Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2017-04-06 Share Issue/Capital Cha…
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Share Capital Increase - 6 April 2017_EN.pdf
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces an increase in share capital due to the exercise of warrants, detailing the number of new shares issued and the resulting total share capital and voting rights. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). The document length is moderate, but the content is a direct announcement of a capital event, not just a notice that a report is available (RPA/RNS).
2017-04-06 English
Share Capital Increase - 6 April 2017_NL.pdf
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated April 6, 2017, announcing a capital increase resulting from the exercise of warrants by management and the resulting change in the total number of shares and voting rights. Key phrases include 'kapitaalverhoging' (capital increase), 'uitoefening van warrants' (exercise of warrants), and disclosure of the new total share count ('maatschappelijk kapitaal' and 'totaal aantal stemrechtverlenende effecten'). This directly relates to changes in the company's capital structure and financing activities. This aligns best with the 'Capital/Financing Update' category (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific corporate finance event.
2017-04-06 Dutch
Galapagos doses first psoriatic arthritis patient with filgotinib
Regulatory Filings Classification · 95% confidence The document is explicitly titled as a "Press release" dated April 5, 2017, announcing a specific operational milestone: the dosing of the first psoriatic arthritis patient with filgotinib, which triggered a milestone payment. This type of announcement, focusing on immediate operational news, clinical trial progress, and partnership updates, is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is a press release announcing key operational and financial triggers (milestone payment), it fits best under the Earnings Release (ER) category, which covers initial announcements of periodical results or significant operational updates, even if it's not a formal quarterly earnings report. It is not a full 10-K, an Audit Report (AR), or a specific financing document (CAP). Given the nature of the announcement (clinical trial progress leading to a payment), ER is the most appropriate fit among the provided options for a time-sensitive, high-impact operational update released via press wire.
2017-04-05 English
Galapagos behandelt eerste psoriatic arthritis patient met filgotinib
Legal Proceedings Report Classification · 99% confidence The document is explicitly titled as a "Persbericht" (Press Release) dated April 5, 2017. It announces a specific operational milestone: the dosing of the first patient in the EQUATOR study for filgotinib, which triggered a milestone payment from Gilead. This type of announcement, focusing on a specific event, partnership update, or clinical trial progress, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a transcript (CT), or a management discussion (MDA), and it is a formal announcement of a material event, it fits best as an Earnings Release (ER) if it were quarterly/periodical results, or RNS if it's a general regulatory update. Given the context of clinical trial progress and milestone payments, which often accompany or precede earnings announcements, ER is a strong candidate, but RNS is the most accurate fallback for non-standard, material press releases. However, many companies issue press releases for clinical trial updates that are not strictly earnings-related but are material to investors. Since the text is a formal press release announcing a clinical trial milestone and partnership update, and it is not a full financial report, it is classified as a Regulatory Filing (RNS) as a general announcement of material information, or potentially ER if this is the primary way they communicate such updates. Given the content is about a clinical trial milestone payment, which is a financial/operational update, ER is plausible, but RNS covers general regulatory announcements best. I will lean towards RNS as the most appropriate general regulatory announcement category for a press release detailing clinical progress and partnership milestones, especially since it mentions compliance with EU Market Abuse Regulation (MAR).
2017-04-05 Dutch
Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib
Regulatory Filings Classification · 90% confidence The document is a press release from Galapagos NV, dated April 4, 2017, announcing the start of three new Phase 2 patient studies for their drug filgotinib in various conditions (Sjögren's syndrome, ankylosing spondylitis, and psoriatic arthritis). This type of announcement, detailing clinical trial progress, drug development updates, and partnership information, is characteristic of communications aimed at investors and the public regarding ongoing research and pipeline development. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). Since it details specific clinical trial plans and drug development progress, it aligns best with general Investor Information or a specific announcement related to the drug pipeline. Given the options, this is a specific announcement about the company's product pipeline and clinical strategy, which often falls under general investor relations material. It is not a Call Transcript (CT), Management Discussion (MDA), or a formal Audit Report (AR). It is most closely related to general corporate updates, but since it focuses heavily on clinical trial initiation and drug development, it is best classified as a general announcement that doesn't fit the highly specific financial report categories. However, looking closely at the definitions, it is a specific announcement about the company's operations and pipeline, which is often released via regulatory channels. Since it is not a formal financial report, nor a management change, nor a dividend notice, and it is a detailed announcement, it fits best as a general Regulatory Filing (RNS) if no better fit exists, or potentially Investor Presentation (IP) if it were a slide deck, which it is not. Given the context of a press release detailing clinical trial progress, it is a significant corporate event announcement. In the absence of a 'Clinical Trial Update' code, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for a detailed, non-financial, operational press release.
2017-04-04 English
Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib
Regulatory Filings Classification · 95% confidence The document is a press release dated April 4, 2017, announcing the initiation of three new Phase 2 Proof-of-Concept studies for the drug filgotinib in various inflammatory conditions (Sjögren's syndrome, ankylosing spondylitis, and psoriatic arthritis). It details the study designs, endpoints, and provides background information on the diseases and the company (Galapagos). This type of announcement, detailing clinical trial progress and pipeline updates, is characteristic of communications aimed at investors and the market regarding drug development activities. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a transcript (CT). Since it is a detailed announcement about clinical development and pipeline strategy, the most appropriate classification among the options is Investor Presentation (IP), as these press releases often serve as the primary source of detailed, non-financial, strategic updates for investors, even if not formally presented as a slide deck. However, given the specific focus on announcing the *initiation* of clinical studies, it functions as a significant corporate update. If the document were a slide deck, IP would be perfect. Since it is a press release detailing clinical trial plans, it is a high-level corporate update. It is not a general regulatory filing (RNS) because it fits better under a specific category related to investor information/pipeline. It is not an Earnings Release (ER) as it contains no financial results. It is not a Management Report (MDA) which usually discusses past financial results. Given the options, 'Investor Presentation' (IP) is the closest fit for a detailed, non-financial, pipeline-focused announcement intended for investors, although 'Regulatory Filings' (RNS) could be a fallback if IP is strictly reserved for slide decks. Given the depth of clinical detail, IP is chosen over the generic RNS.
2017-04-04 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.